Endogenous interleukin I receptor antagonist during human bone marrow transplantation: Increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy

Transplantation

Volumn 63, Issue 1, 1997, Pages 52-56

  Schwaighofer, Hubert ^a,b   Oberhuber, Georg ^a   Hebart, Holger ^c   Einsele, Hermann ^c   Herold, Manfred ^a   Nachbaur, David ^a   Eibl, Brigitte ^a   Tilg, Herbert ^a   Kropshofer, Gabriele ^a   Ferrara, James L M ^d   Niederwieser, Dietger ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IL1RN PROTEIN, HUMAN; MONOCLONAL ANTIBODY; SIALOGLYCOPROTEIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; T LYMPHOCYTE ACTIVATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; METABOLISM; MIDDLE AGED; SECRETION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; SIALOGLYCOPROTEINS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030614515     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199701150-00010     Document Type: Article

References (43)

1. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517.
2. De Witte T, Zwaan FE, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the leukemia working party of the European bone marrow transplantation group (EBMTG). Br J Haematol 1990; 74: 151.
3. Storb R, Prentice RL, Thomas ED. Treatment of aplastic anemia by marrow transplantation from HLA-identical siblings. J Clin Invest 1977; 59: 625.
4. Appelbaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and bone marrow transplantation. J Clin Oncol 1987; 5: 1340.
5. Broxmeyer HE. Interacting effects of cytokines on hematopoietic stem and progenitor cells. In: Mertelsmann R, Herrmann F, ed. Hematopoietic growth factors in clinical applications. New York: Dekker, 1990; 3.
6. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964.
7. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
8. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor alpha (TNF-alpha) precede major complications of bone marrow transplantation. Blood 1990; 75: 1011.
9. Niederwieser D, Troppmair J, Adolph G, Margreiter R, Huber C. Role of lymphokines in the induction of graft versus host disease. Exp Hematol 1985; 13: 131.
10. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-γ during human bone marrow transplantation: analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620.
11. Atkinson K, Matias C, Guiffre A, et al. In vivo administration of granulocyte colony-stimulating (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376.
12. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627.
13. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518.
14. Moore MA, Warren DJ. Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci 1987; 84: 7134.
15. Fibbe WE, Falkenburg JH. Regulation of hematopoiesis by interleukin-1. Biotherapy 1990; 2: 325.
16. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106.
17. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167.
18. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404.
19. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423.
20. Fischer E, van Zee KJ, Marano MA, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992; 79: 2196.
21. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987; 2: 1240.
22. Tilg H, Vogel W, Wiedermann CJ, et al. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology 1993; 18: 1132.
23. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC. Balance of synovial fluid IL-1 beta and Il-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993; 341: 146.
24. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Immunol Today 1993; 14: 260.
25. Ohlsson K, Björk P, Bergenfeld M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550.
26. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338.
27. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915.
28. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342.
29. Speck B. Bone marrow transplantation in leukemia. Anticancer Res 1981; 1: 249.
30. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
31. Einsele H, Steidle H, Vallbracht A, Saal JG, Ehninger G, Müller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104.
32. Einsele H, Ehninger G, Steidle M, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170.
33. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 1.
34. Aulitzky WE, Schulz TF, Tilg H, et al. Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J Infect Dis 1991; 163: 1344.
35. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78: 1275.
36. Schur PH, Chang DM, Baptiste P, Uhteg LC, Hanson DC. Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals. Clin Immunol Immunopathol 1990; 57: 45.
37. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994; 84: 4142.
38. Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993; 150: 4687.
39. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794.
40. Stein J, Volk HD, Liebenthal C, Krüger DH, Prösch S. Tumor necrosis factor-α stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol 1993; 74: 2333.
41. Shanley JD, Goff E, Debs RJ, Forman SJ. The role of tumor necrosis factor-α in acute murine cytomegalovirus infection in BALB/c mice. J Infect Dis 1994; 169: 1088.
42. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705.
43. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136.